Life
FDA Requests Additional Information on Eli Lilly's Obesity Medication Foundayo
Eli Lilly's obesity treatment, Foundayo, is under increased scrutiny as the FDA seeks more data regarding potential liver injury risks associated with the drug.
editorial-staff
1 min read
Updated about 9 hours ago
Summary
The FDA has requested further information from Eli Lilly concerning its obesity medication, Foundayo, amid concerns about possible liver injuries linked to the drug.
This development marks a significant moment for Eli Lilly as it navigates regulatory challenges associated with the approval of Foundayo.
In addition to the liver injury concerns, recent updates have also highlighted a win for the pharmaceutical sector related to the 340B program.
Updates
- No subsequent updates recorded.